Home
    • Plans Blog Contact
    Teva Pharmaceutical Industries Limited logo

    Teva Pharmaceutical Industries Limited

    TEVJF
    Last price US$33.00
    Market cap US$38.4b
    12M price change 85.39%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    NewBridge Global Ventures, Inc.NBGV Industry peer Phoenix Life Sciences International LimitedPLSI Industry peer Amryt Pharma plcAMYT Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Teva Pharmaceutical Industries Limited Overview

    Industry: Drug Manufacturers—Specialty & Generic

    Sector: Healthcare

    Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Teva Pharmaceutical Industries Limited into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 29, 2026

    Quarterly result summary

    Revenue was $578M (+41% YoY); EPS was $0.31 (reported).

    Revenue $578M +41% YoY
    EPS $0.31 reported
    Operating income $3.8 reported
    Net income $369M +68% YoY

    What changed

    • Revenue +41% YoY to $578M; EPS reported to $0.31.
    • Capital return update: free cash flow $188M.
    • Net income +68% YoY to $369M.

    Guidance / outlook

    We expect our annual non-GAAP tax rate for 2026 to be between 20%-23% (16%-19% stand-alone), higher than our non-GAAP tax rate for 2025, which was 15.8%.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Apr 29, 2026 SEC filing FORM 8-K Apr 29, 2026 SEC filing 10-K Feb 03, 2026 SEC filing FORM 8-K Jan 28, 2026 Earnings release PRESS RELEASE Jan 28, 2026 SEC filing FORM 8-K Jan 12, 2026 Earnings material PRESS RELEASE Jan 12, 2026 SEC filing 10-Q Nov 05, 2025 SEC filing FORM 8-K Nov 05, 2025 Earnings release PRESS RELEASE Nov 05, 2025 SEC filing 10-Q Jul 30, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Teva Pharmaceutical Industries Limited earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers—Specialty & Generic industry , NewBridge Global Ventures, Inc. , Phoenix Life Sciences International Limited , Amryt Pharma plc are companies with high ratings.

    Return on Equity

    Score 1.95/5
    Teva Pharmaceutical Industries Limited exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Teva Pharmac... TEVJF US$38.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.18/5
    Teva Pharmaceutical Industries Limited commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Teva Pharmac... TEVJF US$38.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers—Specialty & Generic industry , NewBridge Global Ventures, Inc. , Phoenix Life Sciences International Limited , Amryt Pharma plc are companies with high ratings.

    Leverage

    Score 1.18/5
    Teva Pharmaceutical Industries Limited registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Teva Pharmac... TEVJF US$38.4b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Teva Pharmaceutical Industries Limited logo

    Teva Pharmaceutical Industries Limited

    US$33.00

    US$2.56

    -92.2% vs price

    US$38.4b

    0.00%

    85.39%